JP2020530299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530299A5 JP2020530299A5 JP2020507586A JP2020507586A JP2020530299A5 JP 2020530299 A5 JP2020530299 A5 JP 2020530299A5 JP 2020507586 A JP2020507586 A JP 2020507586A JP 2020507586 A JP2020507586 A JP 2020507586A JP 2020530299 A5 JP2020530299 A5 JP 2020530299A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- appendix
- cell
- binding
- binding substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023103640A JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542920P | 2017-08-09 | 2017-08-09 | |
| US62/542,920 | 2017-08-09 | ||
| PCT/US2018/045741 WO2019032661A1 (en) | 2017-08-09 | 2018-08-08 | CD8 LIAISON AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103640A Division JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530299A JP2020530299A (ja) | 2020-10-22 |
| JP2020530299A5 true JP2020530299A5 (https=) | 2021-09-16 |
| JP7347899B2 JP7347899B2 (ja) | 2023-09-20 |
Family
ID=65272669
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507586A Active JP7347899B2 (ja) | 2017-08-09 | 2018-08-08 | Ｃｄ８結合物質 |
| JP2023103640A Pending JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A Pending JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103640A Pending JP2023112153A (ja) | 2017-08-09 | 2023-06-23 | Ｃｄ８結合物質 |
| JP2025076447A Pending JP2025109736A (ja) | 2017-08-09 | 2025-05-01 | Ｃｄ８結合物質 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11566072B2 (https=) |
| EP (1) | EP3665201A4 (https=) |
| JP (3) | JP7347899B2 (https=) |
| CN (1) | CN111511763B (https=) |
| CA (1) | CA3069930A1 (https=) |
| WO (1) | WO2019032661A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111511763B (zh) * | 2017-08-09 | 2024-05-31 | 奥里尼斯生物科学有限公司 | Cd8结合剂 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR102877915B1 (ko) | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| WO2020239945A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| TWI873176B (zh) * | 2019-09-04 | 2025-02-21 | 美商建南德克公司 | Ｃｄ８結合劑及其用途 |
| EP4041297A4 (en) * | 2019-10-11 | 2024-02-28 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS FOR TREATING ACUTE MYELOID LEUKEMIA |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| WO2022011005A1 (en) * | 2020-07-07 | 2022-01-13 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| CN116723857A (zh) * | 2020-07-21 | 2023-09-08 | 苏州智核生物医药科技有限公司 | Cd8结合多肽及其用途 |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
| MX2023008081A (es) | 2021-01-11 | 2023-09-12 | Sana Biotechnology Inc | Uso de vectores virales dirigidos a cd8. |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| CN114230665B (zh) * | 2021-06-23 | 2024-03-22 | 苏州智核生物医药科技有限公司 | CD8α结合多肽及其用途 |
| WO2023076876A1 (en) * | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| IL313877A (en) * | 2021-12-29 | 2024-08-01 | Univ Rutgers | Antibodies with high affinity to a single site and methods of using them |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024156881A1 (en) * | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69007975T2 (de) | 1989-08-22 | 1994-07-21 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2000055305A1 (en) | 1999-03-12 | 2000-09-21 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating cd8+ cells, and related hybridoma cells, antibodies and polypeptides |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| ES2993140T3 (en) * | 2010-04-02 | 2024-12-23 | Amunix Pharmaceuticals Inc | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| ES2694180T3 (es) | 2012-01-20 | 2018-12-18 | Vib Vzw | Citocinas de haz alfa-helicoidal mutantes dirigidas |
| PT2822575T (pt) | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| CN104379169A (zh) * | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| US10101324B2 (en) * | 2012-12-03 | 2018-10-16 | The Regents Of The University Of California | Non-competitive immunoassays to detect small molecules using nanopeptamers |
| US20150368339A1 (en) | 2013-02-05 | 2015-12-24 | Vib Vzw | Muscarinic acetylcholine receptor binding agents and uses thereof |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| KR102322510B1 (ko) | 2013-07-18 | 2021-11-08 | 브이아이비 브이지더블유 | 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인 |
| JP6595988B2 (ja) | 2013-07-19 | 2019-10-23 | ヴィブ ブイゼットダブリュー | ターゲットされる修飾ｔｎｆファミリーメンバー |
| SG10202010429YA (en) | 2013-07-19 | 2020-11-27 | Vib Vzw | Targeting of cytokine antagonists |
| BR112016001128A2 (pt) | 2013-07-19 | 2018-01-23 | Vib Vzw | membros da família il-1 modificados direcionados |
| PT3444271T (pt) | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2018077893A1 (en) * | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CN111511763B (zh) * | 2017-08-09 | 2024-05-31 | 奥里尼斯生物科学有限公司 | Cd8结合剂 |
-
2018
- 2018-08-08 CN CN201880065719.XA patent/CN111511763B/zh active Active
- 2018-08-08 JP JP2020507586A patent/JP7347899B2/ja active Active
- 2018-08-08 WO PCT/US2018/045741 patent/WO2019032661A1/en not_active Ceased
- 2018-08-08 CA CA3069930A patent/CA3069930A1/en active Pending
- 2018-08-08 EP EP18844218.0A patent/EP3665201A4/en active Pending
- 2018-08-08 US US16/634,325 patent/US11566072B2/en active Active
-
2022
- 2022-12-01 US US18/060,694 patent/US12448447B2/en active Active
-
2023
- 2023-06-23 JP JP2023103640A patent/JP2023112153A/ja active Pending
-
2025
- 2025-05-01 JP JP2025076447A patent/JP2025109736A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530299A5 (https=) | ||
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| JP2020506727A5 (https=) | ||
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| JP2020530298A5 (https=) | ||
| JP7656401B2 (ja) | バイシストロン性キメラ抗原受容体及びそれらの使用 | |
| Andreu-Saumell et al. | CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition | |
| US10738116B2 (en) | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors | |
| US10562952B2 (en) | Anti-CD276 chimeric antigen receptors | |
| JP2020505955A5 (https=) | ||
| JP6449359B2 (ja) | 免疫原性の低いｔ細胞及び／又はｂ細胞エピトープを有するシュードモナス外毒素ａ | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| JP2019534246A5 (https=) | ||
| JP2024500847A5 (https=) | ||
| JP2023546725A5 (https=) | ||
| JP2024037918A (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| CN113862292A (zh) | 嵌合抗原受体、组合物以及方法 | |
| CN108463469B (zh) | 一种与抗可替宁抗体连接的嵌合抗原受体及其用途 | |
| US20160333422A1 (en) | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors | |
| CN114364801A (zh) | 用于用抗bcma免疫治疗来治疗癌症的组合物和方法 | |
| JP2022512541A5 (https=) | ||
| JP2020516681A5 (https=) | ||
| Siegemund et al. | IgG-single-chain TRAIL fusion proteins for tumour therapy | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| CA3232668A1 (en) | Switch receptors using il-9 signaling domains |